与定量气雾剂相比，储雾罐和易纳器的支气管扩张作用。
Bronchodilator effect of Aerochamber and Inspirease in comparison with metered dose inhaler.
作者信息
Crimi N, Palermo F, Cacopardo B, Vancheri C, Oliveri R, Palermo B, Mistretta A
机构信息
Institute of Respiratory Diseases, University of Catania, Italy.
出版信息
Eur J Respir Dis. 1987 Sep;71(3):153-7.
This trial was performed in a randomized double-blind manner on four different days in 13 asthmatic patients in order to compare the bronchodilator efficacy of two different inhalation devices, Inspirease (IP) and Aerochamber (AC), to the conventional metered dose inhaler (MDI). The results showed that clenbuterol determined a significant FEV1 increase inhaled either via MDI or via IP and AC. IP caused a greater bronchodilatation than AC, 30 min after clenbuterol administration. IP caused a greater mean increase (P less than 0.05) in FEV1 than the MDI at all time intervals; AC provided an improvement in bronchodilator response over directly administered MDI. Such responses are only marginally clinically relevant when patients use MDI correctly. These devices are mainly indicated in patients with poor hand-lung coordination.
该试验以随机双盲方式，于4个不同日期对13名哮喘患者进行，目的是比较两种不同吸入装置（Inspirease，简称IP；Aerochamber，简称AC）与传统定量气雾剂（MDI）的支气管扩张疗效。结果显示，沙丁胺醇通过MDI、IP或AC吸入后，均可使FEV1显著增加。给药30分钟后，IP引起的支气管扩张作用大于AC。在所有时间间隔内，IP引起的FEV1平均增加幅度均大于MDI（P<0.05）；与直接使用MDI相比，AC使支气管扩张反应有所改善。当患者正确使用MDI时，这些反应在临床上仅有轻微相关性。这些装置主要适用于手肺协调性差的患者。
Zotero 插件